The NOG mouse was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdc scid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The NOG mouse was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdc scid line for a total of eight generations. The HSVtk transgene was generated by CIEA via microinjection into NOD/Shi inbred mice. The transgenic construct contains the mouse albumin enhancer/promoter (mAlb En/Pro), the chimeric intron, HSVtk cDNA, and the 3'-UTR of the human growth hormone gene with a polyadenylation signal (hGH pA). There was a single site of transgene integration, and HSVtk mRNA was selectively expressed in the liver. The TK-NOD/Shi mice were backcrossed onto the NOG mouse at CIEA and imported into Taconic in 2014.
Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M, Wakui M, Ito M, Suematsu M, Peltz G, Nakamura M, Suemizu H. The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. (2011) Biochem Biophys Res Commun. 18;405(3):405-10.
Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. (2002) NOD/SCID/γ mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9):3175-3182.